Tarsus Pharmaceuticals (TARS) Cash from Investing Activities (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$58.6 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 67.6% year-over-year to -$58.6 million; the TTM figure through Mar 2026 stood at -$65.7 million (up 50.17% YoY), while the FY2025 annual figure was -$42.1 million, up 78.86% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$58.6 million, down from $49.3 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $64.1 million in Q2 2023, with the low at -$102.2 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is -$4.7 million (2025), against an average of -$17.9 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 47112.4% in 2022, then surged 52634.43% in 2023.
• Tarsus Pharmaceuticals' Cash from Investing Activities stood at -$87.2 million in 2022, then soared by 120.47% to $17.8 million in 2023, then sank by 433.75% to -$59.6 million in 2024, then soared by 182.71% to $49.3 million in 2025, then slumped by 218.85% to -$58.6 million in 2026.
• Business Quant data shows TARS's Cash from Investing Activities at -$58.6 million in Q1 2026, $49.3 million in Q4 2025, and -$4.7 million in Q3 2025.